Elevated carcinoembryonic antigen [CEA] 1 R97.0 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. 2 The 2021 edition of ICD-10-CM R97.0 became effective on October 1, 2020. 3 This is the American ICD-10-CM version of R97.0 - other international versions of ICD-10 R97.0 may differ. More ...
Other abnormal tumor markers. R97.8 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2019 edition of ICD-10-CM R97.8 became effective on October 1, 2018.
Elevated ca 27-30 ICD-10-CM R97.8 is grouped within Diagnostic Related Group (s) (MS-DRG v38.0): 947 Signs and symptoms with mcc 948 Signs and symptoms without mcc
Elevated carcinoembryonic antigen [CEA] R97. 0 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM R97. 0 became effective on October 1, 2021.
CEA is a protein polysaccharide found in some carcinomas. It is effective as a biochemical marker for monitoring the response of certain malignancies to therapy. CEA may be medically necessary for follow-up of patients with colorectal carcinoma.
The carcinoembryonic antigen (CEA) test measures the level of CEA in the blood. CEA is a protein normally found in the tissue of a developing baby in the womb. The blood level of this protein disappears or becomes very low after birth. In adults, an abnormal level of CEA may be a sign of cancer.
To summarize, NCD 190.26 provides, under the heading “Indications,” that a CEA test “may be medically necessary,” and thus covered by Medicare, for two broad groups of patients: (1) patients with colorectal cancer; and (2) patients with other types of cancer when the cancer tumor does not express a “more specific ...
The CEA is measured in the blood and the normal range is <2.5 ng/ml in an adult non-smoker and <5.0 ng/ml in a smoker. The most common cancers that elevate CEA are in the colon and rectum but it can be elevated with gastric, ovarian and other cancers.
Sensitivity of CEA ranged from 17.4 % to 100 %, specificity ranged from 66.1 % to 98.4 %, positive predictive value ranged from 45.8 % to 95.2% and negative predictive value ranged from 74.5 % to 100 %.
CEA is a type of tumor marker. Tumor markers are substances made by cancer cells or by normal cells in response to cancer in the body. A high level of CEA can be a sign of certain types of cancers. These include cancers of the colon and rectum, prostate, ovary, lung, thyroid, or liver.
CEA testing is not used to diagnose cancer, but it may assist doctors in predicting how a person's cancer may be likely to progress, determining treatment effectiveness, and assessing whether or not cancer has returned after treatment.
SARS-CoV-2 infection might be another cause of CEA elevation, with nearly 20% of patients experienced transient and marked CEA increment during COVID-19 pneumonia. The false-positive results of CEA elevation might have clinical significance for patients with colorectal cancer.
CEAORDERING INFORMATION:Geisinger Epic Procedure Code: LAB1969 Geisinger Epic ID: 6523Preferred collection container:Stat/Line draws: 3 mL green/yellow-top (plasma separator) tube Routine requests/off-site specimens: 3.5 mL gold-top (serum separator) tubeSpecimen required:2 mL of serum or plasma; minimum 0.5 mL18 more rows•Feb 18, 2022
This assay is intended for the in vitro quantitative determination of carcinoembryonic antigen in human serum and plasma. 1 The Elecsys CEA assay is further indicated for serial measurement of CEA to aid in the management of cancer patients. The main indication for CEA determinations is the follow-up and therapy-management of colorectal carcinoma.
As with all tests containing monoclonal mouse antibodies, erroneous findings may be obtained from samples taken from patients who have been treated with monoclonal mouse antibodies or have received them for diagnostic purposes . 1
CEA determinations are not recommended for cancer screening in the general population. CEA concentrations within the normal range do not exclude the possible presence of a malignant disease.